HomeBAVA • VIE
add
Bavarian Nordic A/S
Previous close
€23.65
Day range
€24.01 - €24.03
Year range
€17.92 - €32.52
Market cap
2.18B USD
Avg Volume
15.00
P/E ratio
-
Dividend yield
-
Primary exchange
CPH
In the news
Financials
Income Statement
Revenue
Net income
| (DKK) | Sep 2025info | Y/Y change |
|---|---|---|
Revenue | 1.79B | 31.65% |
Operating expense | 548.52M | 12.86% |
Net income | 1.09B | 1,450.31% |
Net profit margin | 60.89 | 1,077.76% |
Earnings per share | — | — |
EBITDA | 515.50M | 105.82% |
Effective tax rate | 6.58% | — |
Balance Sheet
Total assets
Total liabilities
| (DKK) | Sep 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 2.98B | 59.08% |
Total assets | 15.16B | 8.68% |
Total liabilities | 2.00B | -38.70% |
Total equity | 13.16B | — |
Shares outstanding | 78.27M | — |
Price to book | 0.14 | — |
Return on assets | 5.93% | — |
Return on capital | 6.76% | — |
Cash Flow
Net change in cash
| (DKK) | Sep 2025info | Y/Y change |
|---|---|---|
Net income | 1.09B | 1,450.31% |
Cash from operations | 1.29B | 1,906.29% |
Cash from investing | -490.06M | -426.39% |
Cash from financing | 68.78M | -37.42% |
Net change in cash | 872.29M | 383.83% |
Free cash flow | 427.65M | 146.76% |
About
Bavarian Nordic A/S is a Danish biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark and Thörishaus near Bern, Switzerland. The company has research and development facilities in Martinsried, Germany, as well as offices in USA, Canada, and France. The company uses viral vectors and virus-like particles in its research and development.
In July 2025, the company agreed to be acquired by private equity firms Permira and Nordic Capital for 19 billion kr. However, in November, the acquisition failed to gain sufficient support from Bavarian Nordic's shareholders, leading to its termination. Wikipedia
CEO
Founded
Jul 1, 1992
Website
Employees
1,738
